



Arecor Therapeutics plc
("Arecor" or the "Group")

**ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF
PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES**

Cambridge, UK, 4 July 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that its abstract titled "Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500" has been selected for presentation as part of the Short Oral Discussion Session A at the 58th Annual Meeting of the European Association for the Study of Diabetes ([EASD](#)) meeting, which will be held from 19-23 September 2022 in Stockholm, Sweden and online.

The presentation will take place on **Tuesday 20 September** during the SO 19 Short Oral Discussion Session "**How complicated is type 1 diabetes?**" (11:45-12:45)

Oral Presentation: Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500
Presenting Author: Dr Eva Svehlikova
Presentation Number: 407
Date and Time: Tuesday, 20 September 2022, between 11:45 and 12:45 (Central European Time)

AT278 is an ultra-concentrated (500U/mL) novel formulation of insulin that has been designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements.

Sarah Howell, Chief Executive Officer at Arecor, said: "AT278 has the potential to be the first, and potentially only, ultra-concentrated (500U/mL) yet ultra-rapid acting insulin. This product offers the potential to significantly improve post prandial control whilst also reducing the injection volume and number of daily injections for the growing population of people living with diabetes who have high daily insulin needs, particularly those with type 2 diabetes. In addition, with its unique profile, AT278 is a key enabler in the development of next generation miniaturised insulin delivery devices, an expected future disrupter in the market. We look forward to sharing our ground-breaking data for this next generation insulin candidate with scientific colleagues in Stockholm and around the world."



About the EASD

The European Association for the Study of Diabetes (EASD) is a non-profit, medical scientific association, founded in 1965 to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. EASD holds its Annual Meeting in a different European city each year with more than 15,000 delegates from over 130 countries attending. The scientific programme includes more than 1,200 talks and presentations on the latest results in diabetes research by leading experts in the field

-ENDS-

For more information, please contact:

Arecor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

About AT278

AT278 is Arecor's ultra-concentrated, ultra-rapid acting insulin designed to accelerate the absorption of insulin post injection, to enable more effective management of blood glucose levels to the increasing number



of people with diabetes with high daily insulin requirements (>200 units/day), whilst maintaining the convenience and compliance benefits of being able to deliver these high insulin doses in a lower injection volume via a single injection. A truly rapid acting concentrated insulin is a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices.